 |
市場調査レポート
商品コード
1285968
非小細胞肺がんの世界市場 - 市場規模、シェア、成長分析：治療法別（標的療法、免疫療法）、業界予測（2023年～2030年）Global Non-Small Cell Lung Cancer Market Size, Share, Growth Analysis, By Therapy(Targeted Therapy, Immunotherapy) - Industry Forecast 2023-2030 |
||||||
| 非小細胞肺がんの世界市場 - 市場規模、シェア、成長分析：治療法別（標的療法、免疫療法）、業界予測（2023年～2030年） |
|
出版日: 2023年04月12日
発行: SkyQuest
ページ情報: 英文 165 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界の非小細胞肺がんの市場規模は、2021年に236億6,489万米ドルとなり、予測期間（2023年～2030年）に13.9%のCAGRで成長し、2022年の269億4,836万米ドルから2030年には763億3,472万米ドルに拡大すると予測されます。
肺がん、特に非小細胞肺がんは、世界中でがん関連死亡の主要な原因となっています。非小細胞肺がんの有病率と発症率の増加は、効果的な診断用具、治療の選択肢、支持療法手段に対する需要を促進します。高齢化、タバコの喫煙、環境汚染物質への曝露、ライフスタイル要因などが、非小細胞肺がんの負担増に寄与しています。
当レポートでは、世界の非小細胞肺がん市場について調査し、市場概要、親市場分析、市場力学と見通し、セグメント・地域別の市場分析、企業プロファイルなどの情報を提供しています。
目次
エグゼクティブサマリー
親市場分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 主要な市場考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- 知財分析
- 貿易分析
- スタートアップ分析
- 原材料分析
- イノベーションマトリックス
- パイプライン製品の分析
- マクロ経済指標
- 主要な投資分析
- 主要な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制状況
- ポーターの分析
- 競合企業間の敵対関係
- 代替品の脅威
- 買い手の交渉力
- 新規参入業者の脅威
- 供給企業の交渉力
- 将来的な混乱に関するSkyquestの特別考察
- 政治的影響
- 経済的影響
- 社会的影響
- 技術的影響
- 環境的影響
- 法的影響
世界の非小細胞肺がん市場：治療法別
- 市場概要
- 標的療法
- 免疫療法
- 化学療法
世界の非小細胞肺がんの市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他欧州
- アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
- ラテンアメリカ
- ブラジル
- その他ラテンアメリカ
- 中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主要な市場参入企業が採用した戦略
- 主要成功戦略
- 開発別
- 企業別
- 年別
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Roche
- AstraZeneca
- Merck & Co.
- Bristol-Myers Squibb
- Pfizer Inc.
- Novartis AG
- Eli Lilly and Company
- Celgene Corporation
- Boehringer Ingelheim
- AbbVie Inc.
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Sanofi S.A.
- GlaxoSmithKline
- Johnson & Johnson
- Amgen Inc.
- Ipsen S.A.
- Eisai Co., Ltd.
- Taiho Oncology, Inc.
- Gilead Sciences, Inc.
Global Non-Small Cell Lung Cancer Market size was valued at USD 23664.89 million in 2021 and is poised to grow from USD 26948.36 million in 2022 to USD 76334.72 million by 2030, growing at a CAGR of 13.9% in the forecast period (2023-2030).
The global non-small cell lung cancer (NSCLC) market refers to the pharmaceutical and biotechnology industry focused on the diagnosis, treatment, and management of non-small cell lung cancer, which is the most common type of lung cancer. NSCLC accounts for a significant portion of lung cancer cases globally and encompasses various subtypes, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. The NSCLC market involves the development of targeted therapies, immunotherapies, chemotherapy, and supportive care options to improve patient outcomes.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Small Cell Lung Cancer Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Segments covered in this report:
The global non-small cell lung cancer market is segmented based on therapy, region. Based on therapy it is categorized into targeted therapy, chemotherapy, and immunotherapy. Based on region it is categorized into: North America, Europe, Asia-Pacific, South America, and MEA.
Driver
Lung cancer, particularly NSCLC, remains a leading cause of cancer-related deaths worldwide. The increasing prevalence and incidence of NSCLC drive the demand for effective diagnostic tools, treatment options, and supportive care measures. Aging populations, tobacco smoking, exposure to environmental pollutants, and lifestyle factors contribute to the rising burden of NSCLC. Precision medicine approaches, such as molecular profiling and genomic testing, have revolutionized the treatment landscape for NSCLC. Targeted therapies that specifically target genetic mutations and alterations in cancer cells have shown promising results in improving patient outcomes. The development of companion diagnostics and personalized treatment strategies fuels the growth of the NSCLC market.
Restraint
NSCLC tumors can develop resistance to targeted therapies and immunotherapies over time. Tumor heterogeneity, the presence of different subclones within a tumor, contributes to treatment resistance and poses challenges in achieving durable responses. Overcoming drug resistance and understanding tumor heterogeneity are ongoing research priorities in the NSCLC market.
Market Trends
The NSCLC market is witnessing a shift towards combination therapies that involve the use of multiple treatment modalities, such as targeted therapies, immunotherapies, and chemotherapy. Combining therapies with different mechanisms of action aims to enhance treatment efficacy, overcome resistance, and improve patient outcomes. Liquid biopsies, which involve the analysis of circulating tumor DNA (ctDNA) and other biomarkers in blood samples, are gaining importance in the diagnosis and monitoring of NSCLC. These non-invasive tests offer the potential for real-time monitoring of tumor mutations and treatment response. Companion diagnostics that identify predictive biomarkers for targeted therapies and immunotherapies continue to play a crucial role in treatment decision-making. The NSCLC market is increasingly focused on patient-centric care, emphasizing the holistic management of patients' physical, emotional
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
- Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
- Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
- Global Non-Small Cell Lung Cancer Market by Therapy
- Market Overview
- Targeted Therapy
- Immunotherapy
- Chemotherapy
- Global Non-Small Cell Lung Cancer Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
- Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
- Key Company Profiles
- Roche
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol-Myers Squibb
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Celgene Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Astellas Pharma Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ipsen S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eisai Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Taiho Oncology, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gilead Sciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
